Application of nanotechnology in improving bioavailability and bioactivity of diet-derived phytochemicals

Journal of Nutritional Biochemistry

Volumn 25, Issue 4, 2014, Pages 363-376

  Wang, Shu ^a   Su, Rui ^a   Nie, Shufang ^a   Sun, Ming ^a   Zhang, Jia ^a   Wu, Dayong ^b   Moustaid Moussa, Naima ^a  

^a TEXAS TECH UNIVERSITY   (United States)

^b TUFTS UNIVERSITY   (United States)

Author keywords

Bioactivities; Biocompatible and biodegradable; Nanoparticles; Nanotechnology; Phytochemicals

Indexed keywords

CHITOSAN; CURCUMIN; EPIGALLOCATECHIN GALLATE; LIPOSOME; NANOCARRIER; NATURAL PRODUCT; PLANT MEDICINAL PRODUCT; POLYGLACTIN; QUERCETIN; RESVERATROL; SOLID LIPID NANOPARTICLE; CATECHIN; EMULSION; LACTIC ACID; MICELLE; NANOPARTICLE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; QUERCITRIN; STILBENE DERIVATIVE;

AQUEOUS SOLUTION; BIOAVAILABILITY; BIOCOMPATIBILITY; BIODEGRADABILITY; BIOLOGICAL ACTIVITY; DIET SUPPLEMENTATION; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; DRUG STABILITY; HUMAN; MICELLE; NANOEMULSION; NANOENCAPSULATION; NANOTECHNOLOGY; NONHUMAN; REVIEW; SUSTAINED DRUG RELEASE; ANALOGS AND DERIVATIVES; CHEMISTRY; EMULSION; PROCEDURES; SOLUBILITY;

BIOLOGICAL AVAILABILITY; CATECHIN; CURCUMIN; EMULSIONS; LACTIC ACID; LIPOSOMES; MICELLES; NANOPARTICLES; NANOTECHNOLOGY; PHYTOCHEMICALS; POLYGLYCOLIC ACID; QUERCETIN; SOLUBILITY; STILBENES;

EID: 84895928174     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2013.10.002     Document Type: Review

References (162)

1. Nishiyama N. Nanomedicine: nanocarriers shape up for long life. Nat Nanotechnol 2007, 2:203-204.
2. Zhang L., Gu F.X., Chan J.M., Wang A.Z., Langer R.S., Farokhzad O.C. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 2008, 83:761-769.
3. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
4. Cheng Z., Al Zaki A., Hui J.Z., Muzykantov V.R., Tsourkas A. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 2012, 338:903-910.
5. Bangham A.D., Horne R.W. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J Mol Biol 1964, 8:660-668.
6. Lasic D.D. Novel applications of liposomes. Trends Biotechnol 1998, 16:307-321.
7. Bangham A.D., Horne R.W., Glauert A.M., Dingle J.T., Lucy J.A. Action of saponin on biological cell membranes. Nature 1962, 196:952-955.
8. Langer R. New methods of drug delivery. Science 1990, 249:1527-1533.
9. Mozafari M.R., Johnson C., Hatziantoniou S., Demetzos C. Nanoliposomes and their applications in food nanotechnology. J Liposome Res 2008, 18:309-327.
10. Newman G.C., Huang C. Structural studies on phophatidylcholine-cholesterol mixed vesicles. Biochemistry 1975, 14:3363-3370.
11. Harrison M., Tomlinson D., Stewart S. Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma. J Clin Oncol 1995, 13:914-920.
12. Mozafari M.R., Pardakhty A., Azarmi S., Jazayeri J.A., Nokhodchi A., Omri A. Role of nanocarrier systems in cancer nanotherapy. J Liposome Res 2009, 19:310-321.
13. Abreu A.S., Castanheira E.M., Queiroz M.J., Ferreira P.M., Vale-Silva L.A., Pinto E. Nanoliposomes for encapsulation and delivery of the potential antitumoral methyl 6-methoxy-3-(4-methoxyphenyl)-1H-indole-2-carboxylate. Nanoscale Res Lett 2011, 6:482.
14. Mozafari M.R. Nanoliposomes: preparation and analysis. Methods Mol Biol 2010, 605:29-50.
15. Shoji Y., Nakashima H. Nutraceutics and delivery systems. J Drug Target 2004, 12:385-391.
16. Li C., Zhang X., Huang X., Wang X., Liao G., Chen Z. Preparation and characterization of flexible nanoliposomes loaded with daptomycin, a novel antibiotic, for topical skin therapy. Int J Nanomedicine 2013, 8:1285-1292.
17. Tang S., Gao D., Zhao T., Zhou J., Zhao X. An evaluation of the anti-tumor efficacy of oleanolic acid-loaded PEGylated liposomes. Nanotechnology 2013, 24:235102.
18. Lasic D.D., Martin F.J., Gabizon A., Huang S.K., Papahadjopoulos D. Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim Biophys Acta 1991, 1070:187-192.
19. Papahadjopoulos D., Allen T.M., Gabizon A., Mayhew E., Matthay K., Huang S.K., et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A 1991, 88:11460-11464.
20. Momekova D., Rangelov S., Yanev S., Nikolova E., Konstantinov S., Romberg B., et al. Long-circulating, pH-sensitive liposomes sterically stabilized by copolymers bearing short blocks of lipid-mimetic units. Eur J Pharm Sci 2007, 32:308-317.
21. Woodle M.C., Lasic D.D. Sterically stabilized liposomes. Biochim Biophys Acta 1992, 1113:171-199.
22. Sharpe M., Easthope S.E., Keating G.M., Lamb H.M. Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma. Drugs 2002, 62:2089-2126.
23. Harris L., Batist G., Belt R., Rovira D., Navari R., Azarnia N., et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002, 94:25-36.
24. Liu F., Liu D. Long-circulating emulsions (oil-in-water) as carriers for lipophilic drugs. Pharm Res 1995, 12:1060-1064.
25. Mun S., Decker E.A., McClements D.J. Influence of droplet characteristics on the formation of oil-in-water emulsions stabilized by surfactant-chitosan layers. Langmuir 2005, 21:6228-6234.
26. McClements D.J., Decker E.A., Weiss J. Emulsion-based delivery systems for lipophilic bioactive components. J Food Sci 2007, 72:R109-R124.
27. McNiff B.L. Clinical use of 10% soybean oil emulsion. Am J Hosp Pharm 1977, 34:1080-1086.
28. Press M., Kikuchi H., Shimoyama T., Thompson G.R. Diagnosis and treatment of essential fatty acid deficiency in man. Br Med J 1974, 2:247-250.
29. Tadros T., Izquierdo P., Esquena J., Solans C. Formation and stability of nano-emulsions. Adv Colloid Interface Sci 2004, 108-109:303-318.
30. Anton N., Vandamme T.F. Nano-emulsions and micro-emulsions: clarifications of the critical differences. Pharm Res 2011, 28:978-985.
31. Pinnamaneni S., Das N.G., Das S.K. Comparison of oil-in-water emulsions manufactured by microfluidization and homogenization. Pharmazie 2003, 58:554-558.
32. Singh B., Bandopadhyay S., Kapil R., Singh R., Katare O. Self-emulsifying drug delivery systems (SEDDS): formulation development, characterization, and applications. Crit Rev Ther Drug Carrier Syst 2009, 26:427-521.
33. Hollman P.C., vd Gaag M., Mengelers M.J., van Trijp J.M., de Vries J.H., Katan M.B. Absorption and disposition kinetics of the dietary antioxidant quercetin in man. Free Radic Biol Med 1996, 21:703-707.
34. Baur J.A., Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006, 5:493-506.
35. Shoba G., Joy D., Joseph T., Majeed M., Rajendran R., Srinivas P.S. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 1998, 64:353-356.
36. Gursoy R.N., Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother 2004, 58:173-182.
37. Khan A.W., Kotta S., Ansari S.H., Sharma R.K., Ali J. Potentials and challenges in self-nanoemulsifying drug delivery systems. Expert Opin Drug Deliv 2012, 9:1305-1317.
38. Puri A., Loomis K., Smith B., Lee J.H., Yavlovich A., Heldman E., et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst 2009, 26:523-580.
39. Muller R.H., Maassen S., Weyhers H., Mehnert W. Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. J Drug Target 1996, 4:161-170.
40. Muller R.H., Mader K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000, 50:161-177.
41. Mehnert W., Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001, 47:165-196.
42. Uner M. Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems. Pharmazie 2006, 61:375-386.
43. Sanad R.A., Abdelmalak N.S., Elbayoomy T.S., Badawi A.A. Formulation of a novel oxybenzone-loaded nanostructured lipid carriers (NLCs). AAPS PharmSciTech 2010, 11:1684-1694.
44. Das S., Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech 2011, 12:62-76.
45. Gokce E.H., Korkmaz E., Dellera E., Sandri G., Bonferoni M.C., Ozer O. Resveratrol-loaded solid lipid nanoparticles versus nanostructured lipid carriers: evaluation of antioxidant potential for dermal applications. Int J Nanomedicine 2012, 7:1841-1850.
46. Aditya N.P., Shim M., Lee I., Lee Y., Im M.H., Ko S. Curcumin and genistein coloaded nanostructured lipid carriers: in vitro digestion and antiprostate cancer activity. J Agric Food Chem 2013, 61:1878-1883.
47. Teeranachaideekul V., Muller R.H., Junyaprasert V.B. Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC)-effects of formulation parameters on physicochemical stability. Int J Pharm 2007, 340:198-206.
48. Jenning V., Lippacher A., Gohla S.H. Medium scale production of solid lipid nanoparticles (SLN) by high pressure homogenization. J Microencapsul 2002, 19:1-10.
49. Puglia C., Bonina F. Lipid nanoparticles as novel delivery systems for cosmetics and dermal pharmaceuticals. Expert Opin Drug Deliv 2012, 9:429-441.
50. Iqbal M.A., Md S., Sahni J.K., Baboota S., Dang S., Ali J. Nanostructured lipid carriers system: recent advances in drug delivery. J Drug Target 2012, 20:813-830.
51. Bargoni A., Cavalli R., Caputo O., Fundaro A., Gasco M.R., Zara G.P. Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats. Pharm Res 1998, 15:745-750.
52. Cavalli R., Bargoni A., Podio V., Muntoni E., Zara G.P., Gasco M.R. Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J Pharm Sci 2003, 92:1085-1094.
53. Torchilin V.P. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res 2007, 24:1-16.
54. Lim S.B., Banerjee A., Onyuksel H. Improvement of drug safety by the use of lipid-based nanocarriers. J Control Release 2012, 163:34-45.
55. Torchilin V.P. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release 2001, 73:137-172.
56. Gong J., Chen M., Zheng Y., Wang S., Wang Y. Polymeric micelles drug delivery system in oncology. J Control Release 2012, 159:312-323.
57. Kwon G.S., Naito M., Yokoyama M., Okano T., Sakurai Y., Kataoka K. Physical entrapment of adriamycin in AB block copolymer micelles. Pharm Res 1995, 12:192-195.
58. Oerlemans C., Bult W., Bos M., Storm G., Nijsen J.F., Hennink W.E. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm Res 2010, 27:2569-2589.
59. Mahapatro A., Singh D.K. Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J Nanobiotechnology 2011, 9:55.
60. Bennet D., Marimuthu M., Kim S., An J. Dual drug-loaded nanoparticles on self-integrated scaffold for controlled delivery. Int J Nanomedicine 2012, 7:3399-3419.
61. Chakraborty S., Stalin S., Das N., Choudhury S.T., Ghosh S., Swarnakar S. The use of nano-quercetin to arrest mitochondrial damage and MMP-9 upregulation during prevention of gastric inflammation induced by ethanol in rat. Biomaterials 2012, 33:2991-3001.
62. Khalil N.M., do Nascimento T.C., Casa D.M., Dalmolin L.F., de Mattos A.C., Hoss I., et al. Pharmacokinetics of curcumin-loaded PLGA and PLGA-PEG blend nanoparticles after oral administration in rats. Colloids Surf B Biointerfaces 2013, 101:353-360.
63. Danhier F., Ansorena E., Silva J.M., Coco R., Le Breton A., Preat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 2012, 161:505-522.
64. Kumari A., Yadav S.K., Pakade Y.B., Singh B., Yadav S.C. Development of biodegradable nanoparticles for delivery of quercetin. Colloids Surf B Biointerfaces 2010, 80:184-192.
65. Kumari A., Yadav S.K., Yadav S.C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 2010, 75:1-18.
66. Albanese A., Tang P.S., Chan W.C. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng 2012, 14:1-16.
67. Peng SF, Tseng MT, Ho YC, Wei MC, Liao ZX, Sung HW, Mechanisms of cellular uptake and intracellular trafficking with chitosan/DNA/poly(gamma-glutamic acid) complexes as a gene delivery vector. Biomaterials;32:239-248.
68. Chiu YL, Ho YC, Chen YM, Peng SF, Ke CJ, Chen KJ, Mi FL, Sung HW: The characteristics, cellular uptake and intracellular trafficking of nanoparticles made of hydrophobically-modified chitosan. J Control Release;146:152-159.
69. Müller R.H., Rühl D., Runge S.A. Biodegradation of solid lipid nanoparticles as a function of lipase incubation time. InInternational Journal of Pharmaceutics 1996, 122:115-121.
70. Olbrich C., Muller R.H. Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures. Int J Pharm 1999, 180:31-39.
71. Heurtault B., Saulnier P., Pech B., Proust J.E., Benoit J.P. A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm Res 2002, 19:875-880.
72. Urbinati G., Marsaud V., Renoir J.M. Anticancer drugs in liposomal nanodevices: a target delivery for a targeted therapy. Curr Top Med Chem 2012, 12:1693-1712.
73. Wang S., Noh S.K., Koo S.I. Epigallocatechin gallate and caffeine differentially inhibit the intestinal absorption of cholesterol and fat in ovariectomized rats. J Nutr 2006, 136:2791-2796.
74. Wang S., Noh S.K., Koo S.I. Green tea catechins inhibit pancreatic phospholipase A(2) and intestinal absorption of lipids in ovariectomized rats. J Nutr Biochem 2006, 17:492-498.
75. Basu A., Lucas E.A. Mechanisms and effects of green tea on cardiovascular health. Nutr Rev 2007, 65:361-375.
76. Chyu K.Y., Babbidge S.M., Zhao X., Dandillaya R., Rietveld A.G., Yano J., et al. Differential effects of green tea-derived catechin on developing versus established atherosclerosis in apolipoprotein E-null mice. Circulation 2004, 109:2448-2453.
77. Proniuk S., Liederer B.M., Blanchard J. Preformulation study of epigallocatechin gallate, a promising antioxidant for topical skin cancer prevention. J Pharm Sci 2002, 91:111-116.
78. de Pace R.C., Liu X., Sun M., Nie S., Zhang J., Cai Q., et al. Anticancer activities of (-)-epigallocatechin-3-gallate encapsulated nanoliposomes in MCF7 breast cancer cells. J Liposome Res 2013, 23:187-196.
79. Barras A., Mezzetti A., Richard A., Lazzaroni S., Roux S., Melnyk P., et al. Formulation and characterization of polyphenol-loaded lipid nanocapsules. Int J Pharm 2009, 379:270-277.
80. Hu B., Ting Y., Zeng X., Huang Q. Bioactive peptides/chitosan nanoparticles enhance cellular antioxidant activity of (-)-epigallocatechin-3-gallate. J Agric Food Chem 2013, 61:875-881.
81. Sanna V., Pintus G., Roggio A.M., Punzoni S., Posadino A.M., Arca A., et al. Targeted biocompatible nanoparticles for the delivery of (-)-epigallocatechin 3-gallate to prostate cancer cells. J Med Chem 2011, 54:1321-1332.
82. Siddiqui I.A., Adhami V.M., Ahmad N., Mukhtar H. Nanochemoprevention: sustained release of bioactive food components for cancer prevention. Nutr Cancer 2010, 62:883-890.
83. Chen L., Lee M.J., Li H., Yang C.S. Absorption, distribution, elimination of tea polyphenols in rats. Drug Metab Dispos 1997, 25:1045-1050.
84. Warden B.A., Smith L.S., Beecher G.R., Balentine D.A., Clevidence B.A. Catechins are bioavailable in men and women drinking black tea throughout the day. J Nutr 2001, 131:1731-1737.
85. Lee M.J., Maliakal P., Chen L., Meng X., Bondoc F.Y., Prabhu S., et al. Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiol Biomarkers Prev 2002, 11:1025-1032.
86. Lambert J.D., Yang C.S. Mechanisms of cancer prevention by tea constituents. J Nutr 2003, 133:3262S-3267S.
87. Hung P.F., Wu B.T., Chen H.C., Chen Y.H., Chen C.L., Wu M.H., et al. Antimitogenic effect of green tea (-)-epigallocatechin gallate on 3T3-L1 preadipocytes depends on the ERK and Cdk2 pathways. Am J Physiol Cell Physiol 2005, 288:C1094-C1108.
88. Kim H., Hiraishi A., Tsuchiya K., Sakamoto K. (-)-Epigallocatechin gallate suppresses the differentiation of 3T3-L1 preadipocytes through transcription factors FoxO1 and SREBP1c. Cytotechnology 2010, 62:245-255.
89. Dube A., Nicolazzo J.A., Larson I. Chitosan nanoparticles enhance the plasma exposure of (-)-epigallocatechin gallate in mice through an enhancement in intestinal stability. Eur J Pharm Sci (pharmacokinetics) 2011, 44:422-426.
90. Hu B., Ting Y., Yang X., Tang W., Zeng X., Huang Q. Nanochemoprevention by encapsulation of (-)-epigallocatechin-3-gallate with bioactive peptides/chitosan nanoparticles for enhancement of its bioavailability. Chem Commun (Camb) 2012, 48:2421-2423.
91. Dube A., Nicolazzo J.A., Larson I. Chitosan nanoparticles enhance the intestinal absorption of the green tea catechins (+)-catechin and (-)-epigallocatechin gallate. Eur J Pharm Sci 2010, 41:219-225.
92. Werle M., Takeuchi H. Chitosan-aprotinin coated liposomes for oral peptide delivery: development, characterisation and in vivo evaluation. Int J Pharm 2009, 370:26-32.
93. Werle M., Takeuchi H., Bernkop-Schnurch A. Modified chitosans for oral drug delivery. J Pharm Sci 2009, 98:1643-1656.
94. Rejman J., Oberle V., Zuhorn I.S., Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J 2004, 377:159-169.
95. Harush-Frenkel O., Debotton N., Benita S., Altschuler Y. Targeting of nanoparticles to the clathrin-mediated endocytic pathway. Biochem Biophys Res Commun 2007, 353:26-32.
96. You J.O., Liu Y.C., Peng C.A. Efficient gene transfection using chitosan-alginate core-shell nanoparticles. Int J Nanomedicine 2006, 1:173-180.
97. Smith A., Giunta B., Bickford P.C., Fountain M., Tan J., Shytle R.D. Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease. Int J Pharm 2010, 389:207-212.
98. Siddiqui I.A., Adhami V.M., Bharali D.J., Hafeez B.B., Asim M., Khwaja S.I., et al. Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res 2009, 69:1712-1716.
99. Bischoff S.C. Quercetin: potentials in the prevention and therapy of disease. Curr Opin Clin Nutr Metab Care 2008, 11:733-740.
100. Yu Y.B., Miyashiro H., Nakamura N., Hattori M., Park J.C. Effects of triterpenoids and flavonoids isolated from Alnus firma on HIV-1 viral enzymes. Arch Pharm Res 2007, 30:820-826.
101. Stewart L.K., Soileau J.L., Ribnicky D., Wang Z.Q., Raskin I., Poulev A., et al. Quercetin transiently increases energy expenditure but persistently decreases circulating markers of inflammation in C57BL/6J mice fed a high-fat diet. Metabolism 2008, 57:S39-S46.
102. Kumari A., Kumar V., Yadav S.K. Plant extract synthesized PLA nanoparticles for controlled and sustained release of quercetin: a green approach. PLoS One 2012, 7:e41230.
103. Srinivas K., King J.W., Howard L.R., Monrad J.K. Solubility and solution thermodynamic properties of quercetin and quercetin dihydrate in subcritical water. J Food Eng 2010, 100:208-218.
104. Tan B.J., Liu Y., Chang K.L., Lim B.K., Chiu G.N. Perorally active nanomicellar formulation of quercetin in the treatment of lung cancer. Int J Nanomedicine 2012, 7:651-661.
105. Song X., Zhao Y., Hou S., Xu F., Zhao R., He J., et al. Dual agents loaded PLGA nanoparticles: systematic study of particle size and drug entrapment efficiency. Eur J Pharm Biopharm 2008, 69:445-453.
106. Bose S., Michniak-Kohn B. Preparation and characterization of lipid based nanosystems for topical delivery of quercetin. Eur J Pharm Sci 2012, 48:442-452.
107. Li H., Zhao X., Ma Y., Zhai G., Li L., Lou H. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release 2009, 133:238-244.
108. Conquer J.A., Maiani G., Azzini E., Raguzzini A., Holub B.J. Supplementation with quercetin markedly increases plasma quercetin concentration without effect on selected risk factors for heart disease in healthy subjects. J Nutr 1998, 128:593-597.
109. Hong Y.J., Mitchell A.E. Metabolic profiling of flavonol metabolites in human urine by liquid chromatography and tandem mass spectrometry. J Agric Food Chem 2004, 52:6794-6801.
110. Murota K., Terao J. Antioxidative flavonoid quercetin: implication of its intestinal absorption and metabolism. Arch Biochem Biophys 2003, 417:12-17.
111. Li W., Yi S., Wang Z., Chen S., Xin S., Xie J., et al. Self-nanoemulsifying drug delivery system of persimmon leaf extract: optimization and bioavailability studies. Int J Pharm 2011, 420:161-171.
112. Volate S.R., Davenport D.M., Muga S.J., Wargovich M.J. Modulation of aberrant crypt foci and apoptosis by dietary herbal supplements (quercetin, curcumin, silymarin, ginseng and rutin). Carcinogenesis 2005, 26:1450-1456.
113. Cruz-Correa M., Shoskes D.A., Sanchez P., Zhao R., Hylind L.M., Wexner S.D., et al. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 2006, 4:1035-1038.
114. Adebamowo C.A., Cho E., Sampson L., Katan M.B., Spiegelman D., Willett W.C., et al. Dietary flavonols and flavonol-rich foods intake and the risk of breast cancer. Int J Cancer 2005, 114:628-633.
115. Nothlings U., Murphy S.P., Wilkens L.R., Henderson B.E., Kolonel L.N. Flavonols and pancreatic cancer risk: the multiethnic cohort study. Am J Epidemiol 2007, 166:924-931.
116. Wang G., Wang J.J., Yang G.Y., Du S.M., Zeng N., Li D.S., et al. Effects of quercetin nanoliposomes on C6 glioma cells through induction of type III programmed cell death. Int J Nanomedicine 2012, 7:271-280.
117. Dhawan S., Kapil R., Singh B. Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery. J Pharm Pharmacol 2011, 63:342-351.
118. Ghosh D., Ghosh S., Sarkar S., Ghosh A., Das N., Das Saha K., et al. Quercetin in vesicular delivery systems: evaluation in combating arsenic-induced acute liver toxicity associated gene expression in rat model. Chem Biol Interact 2010, 186:61-71.
119. Chen-yu G., Chun-fen Y., Qi-lu L., Qi T., Yan-wei X., Wei-na L., et al. Development of a quercetin-loaded nanostructured lipid carrier formulation for topical delivery. Int J Pharm 2012, 430:292-298.
120. Orallo F. Comparative studies of the antioxidant effects of cis- and trans-resveratrol. Curr Med Chem 2006, 13:87-98.
121. Sanna V., Roggio A.M., Siliani S., Piccinini M., Marceddu S., Mariani A., et al. Development of novel cationic chitosan-and anionic alginate-coated poly(d,l-lactide-co-glycolide) nanoparticles for controlled release and light protection of resveratrol. Int J Nanomedicine 2012, 7:5501-5516.
122. Detoni C.B., Souto G.D., da Silva A.L., Pohlmann A.R., Guterres S.S. Photostability and skin penetration of different E-resveratrol-loaded supramolecular structures. Photochem Photobiol 2012, 88:913-921.
123. Teskac K., Kristl J. The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. Int J Pharm 2010, 390:61-69.
124. Neves A.R., Lúcio M., Martins S., Lima J.L., Reis S. Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability. Int J Nanomedicine 2013, 8:177-187.
125. Shao J., Li X., Lu X., Jiang C., Hu Y., Li Q., et al. Enhanced growth inhibition effect of resveratrol incorporated into biodegradable nanoparticles against glioma cells is mediated by the induction of intracellular reactive oxygen species levels. Colloids Surf B Biointerfaces 2009, 72:40-47.
126. Lu X., Ji C., Xu H., Li X., Ding H., Ye M., et al. Resveratrol-loaded polymeric micelles protect cells from Abeta-induced oxidative stress. Int J Pharm 2009, 375:89-96.
127. Frozza R.L., Bernardi A., Paese K., Hoppe J.B., da Silva T., Battastini A.M., et al. Characterization of trans-resveratrol-loaded lipid-core nanocapsules and tissue distribution studies in rats. J Biomed Nanotechnol 2010, 6:694-703.
128. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.
129. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W., et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275:218-220.
130. Lee C.W., Yen F.L., Huang H.W., Wu T.H., Ko H.H., Tzeng W.S., et al. Resveratrol nanoparticle system improves dissolution properties and enhances the hepatoprotective effect of resveratrol through antioxidant and anti-inflammatory pathways. J Agric Food Chem 2012, 60:4662-4671.
131. Guo L., Peng Y., Yao J., Sui L., Gu A., Wang J. Anticancer activity and molecular mechanism of resveratrol-bovine serum albumin nanoparticles on subcutaneously implanted human primary ovarian carcinoma cells in nude mice. Cancer Biother Radiopharm 2010, 25:471-477.
132. Anand P., Thomas S.G., Kunnumakkara A.B., Sundaram C., Harikumar K.B., Sung B., et al. Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol 2008, 76:1590-1611.
133. Bansal S.S., Goel M., Aqil F., Vadhanam M.V., Gupta R.C. Advanced drug delivery systems of curcumin for cancer chemoprevention. Cancer Prev Res (Phila) 2011, 4:1158-1171.
134. Nair K.L., Thulasidasan A.K., Deepa G., Anto R.J., Kumar G.S. Purely aqueous PLGA nanoparticulate formulations of curcumin exhibit enhanced anticancer activity with dependence on the combination of the carrier. Int J Pharm 2012, 425:44-52.
135. Xie X., Tao Q., Zou Y., Zhang F., Guo M., Wang Y., et al. PLGA nanoparticles improve the oral bioavailability of curcumin in rats: characterizations and mechanisms. J Agric Food Chem 2011, 59:9280-9289.
136. Kim T.H., Jiang H.H., Youn Y.S., Park C.W., Tak K.K., Lee S., et al. Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity. Int J Pharm 2011, 403:285-291.
137. Mohanty C., Sahoo S.K. The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials 2010, 31:6597-6611.
138. Yallapu M.M., Gupta B.K., Jaggi M., Chauhan S.C. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. J Colloid Interface Sci 2010, 351:19-29.
139. Kakkar V., Singh S., Singla D., Kaur I.P. Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin. Mol Nutr Food Res 2011, 55:495-503.
140. Shaikh J., Ankola D.D., Beniwal V., Singh D., Kumar M.N. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci 2009, 37:223-230.
141. Wahlstrom B., Blennow G. A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol (Copenh) 1978, 43:86-92.
142. Anand P., Kunnumakkara A.B., Newman R.A., Aggarwal B.B. Bioavailability of curcumin: problems and promises. Mol Pharm 2007, 4:807-818.
143. Cheng A.L., Hsu C.H., Lin J.K., Hsu M.M., Ho Y.F., Shen T.S., et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001, 21:2895-2900.
144. Lao C.D., Ruffin MTt, Normolle D., Heath D.D., Murray S.I., Bailey J.M., et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006, 6:10.
145. Gao Y., Wang C., Sun M., Wang X., Yu A., Li A., et al. In vivo evaluation of curcumin loaded nanosuspensions by oral administration. J Biomed Nanotechnol 2012, 8:659-668.
146. Yu H., Huang Q. Improving the oral bioavailability of curcumin using novel organogel-based nanoemulsions. J Agric Food Chem 2012, 60:5373-5379.
147. Tsai Y.M., Chien C.F., Lin L.C., Tsai T.H. Curcumin and its nano-formulation: the kinetics of tissue distribution and blood-brain barrier penetration. Int J Pharm 2011, 416:331-338.
148. Anand P., Nair H.B., Sung B., Kunnumakkara A.B., Yadav V.R., Tekmal R.R., et al. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol 2010, 79:330-338.
149. Gao Y., Li Z., Sun M., Li H., Guo C., Cui J., et al. Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer. Drug Dev Ind Pharm 2010, 36:1225-1234.
150. Doggui S., Sahni J.K., Arseneault M., Dao L., Ramassamy C. Neuronal uptake and neuroprotective effect of curcumin-loaded PLGA nanoparticles on the human SK-N-SH cell line. J Alzheimers Dis 2012, 30:377-392.
151. Wang W., Zhu R., Xie Q., Li A., Xiao Y., Li K., et al. Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles. Int J Nanomedicine 2012, 7:3667-3677.
152. Yekollu S.K., Thomas R., O'Sullivan B. Targeting curcusomes to inflammatory dendritic cells inhibits NF-kappaB and improves insulin resistance in obese mice. Diabetes 2011, 60:2928-2938.
153. Punfa W., Yodkeeree S., Pitchakarn P., Ampasavate C., Limtrakul P. Enhancement of cellular uptake and cytotoxicity of curcumin-loaded PLGA nanoparticles by conjugation with anti-P-glycoprotein in drug resistance cancer cells. Acta Pharmacol Sin 2012, 33:823-831.
154. Rocha S., Generalov R., Pereira M.O.C., Peres I., Juzenas P., Coelho M.A. Epigallocatechin gallate-loaded polysaccharide nanoparticles for prostate cancer chemoprevention. Nanomedicine (Lond) 2011, 6:79-87.
155. Weiss-Angeli V., Poletto F.S., de Marco S.L., Salvador M., da Silveira N.P., Guterres S.S., et al. Sustained antioxidant activity of quercetin-loaded lipid-core nanocapsules. J Nanosci Nanotechnol 2012, 12:2874-2880.
156. Song Z., Feng R., Sun M., Guo C., Gao Y., Li L., et al. Curcumin-loaded PLGA-PEG-PLGA triblock copolymeric micelles: preparation, pharmacokinetics and distribution in vivo. J Colloid Interface Sci 2011, 354:116-123.
157. Kakkar V., Singh S., Singla D., Sahwney S., Chauhan A.S., Singh G., et al. Pharmacokinetic applicability of a validated liquid chromatography tandem mass spectroscopy method for orally administered curcumin loaded solid lipid nanoparticles to rats. J Chromatogr B Analyt Technol Biomed Life Sci 2010, 878:3427-3431.
158. Desai N. Challenges in development of nanoparticle-based therapeutics. AAPS J 2012, 14:282-295.
159. Duncan R., Gaspar R. Nanomedicine(s) under the microscope. Mol Pharm 2011, 8:2101-2141.
160. Wei A., Mehtala J.G., Patri A.K. Challenges and opportunities in the advancement of nanomedicines. J Control Release 2012, 164:236-246.
161. Jain R.K., Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010, 7:653-664.
162. Srinivas P.R., Philbert M., Vu T.Q., Huang Q., Kokini J.L., Saltos E., et al. Nanotechnology research: applications in nutritional sciences. J Nutr 2010, 140:119-124.